These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

345 related items for PubMed ID: 20067434

  • 1. Effects of beta-blockers on glucose and lipid metabolism.
    Fonseca VA.
    Curr Med Res Opin; 2010 Mar; 26(3):615-29. PubMed ID: 20067434
    [Abstract] [Full Text] [Related]

  • 2. Optimizing treatment of diabetes and cardiovascular disease with combined alpha,beta-blockade.
    Bell DS.
    Curr Med Res Opin; 2005 Aug; 21(8):1191-200. PubMed ID: 16083528
    [Abstract] [Full Text] [Related]

  • 3. Beta-blockers in hypertension.
    Ram CV.
    Am J Cardiol; 2010 Dec 15; 106(12):1819-25. PubMed ID: 21126627
    [Abstract] [Full Text] [Related]

  • 4. Beta-blocker underuse in secondary prevention of myocardial infarction.
    Everly MJ, Heaton PC, Cluxton RJ.
    Ann Pharmacother; 2004 Feb 15; 38(2):286-93. PubMed ID: 14742768
    [Abstract] [Full Text] [Related]

  • 5. [Calcium antagonists in cardiovascular disease. Clinical evidence from morbidity and mortality trials].
    Oparil S, Bakir SE.
    Drugs; 2000 Feb 15; 59 Spec No 2():25-37. PubMed ID: 11002856
    [Abstract] [Full Text] [Related]

  • 6. Should beta-blockers be used to control hypertension in people with chronic kidney disease?
    Hart PD, Bakris GL.
    Semin Nephrol; 2007 Sep 15; 27(5):555-64. PubMed ID: 17868793
    [Abstract] [Full Text] [Related]

  • 7. The vasodilatory beta-blockers.
    Pedersen ME, Cockcroft JR.
    Curr Hypertens Rep; 2007 Aug 15; 9(4):269-77. PubMed ID: 17686376
    [Abstract] [Full Text] [Related]

  • 8. Atenolol as a comparator in outcome trials in hypertension: a correct choice in the past, but not for the future?
    Dahlöf B, Devereux RB, Kjeldsen SE, Lyle PA, Zhang Z, Edelman JM.
    Blood Press; 2007 Aug 15; 16(1):6-12. PubMed ID: 17453746
    [Abstract] [Full Text] [Related]

  • 9. Are tolerability concerns a class effect of beta-blockers in treating patients with hypertension?
    Kountz DS.
    Postgrad Med; 2009 Jan 15; 121(1):14-24. PubMed ID: 19179810
    [Abstract] [Full Text] [Related]

  • 10. Nebivolol: a third-generation beta-blocker for hypertension.
    Cheng JW.
    Clin Ther; 2009 Mar 15; 31(3):447-62. PubMed ID: 19393838
    [Abstract] [Full Text] [Related]

  • 11. Are we misunderstanding beta-blockers.
    Cruickshank JM.
    Int J Cardiol; 2007 Aug 09; 120(1):10-27. PubMed ID: 17433471
    [Abstract] [Full Text] [Related]

  • 12. Do beta-blockers prolong survival in chronic heart failure? A review of the experimental and clinical evidence.
    Packer M.
    Eur Heart J; 1998 Feb 09; 19 Suppl B():B40-6. PubMed ID: 9519351
    [Abstract] [Full Text] [Related]

  • 13. [Retrospective studies and prospects of therapy for hypertension].
    Maisch B, Brilla C, Kruse T, Noll B, Bethge C.
    Herz; 1995 Dec 09; 20(6):370-89. PubMed ID: 8582697
    [Abstract] [Full Text] [Related]

  • 14. Beta-blockers in the treatment of hypertension: are there clinically relevant differences?
    Weir MR.
    Postgrad Med; 2009 May 09; 121(3):90-8. PubMed ID: 19491545
    [Abstract] [Full Text] [Related]

  • 15. An in-depth analysis of vasodilation in the management of hypertension: focus on adrenergic blockade.
    Bakris G.
    J Cardiovasc Pharmacol; 2009 May 09; 53(5):379-87. PubMed ID: 19454898
    [Abstract] [Full Text] [Related]

  • 16. Haemodynamic consequences of intrinsic sympathomimetic activity in relation to changes in plasma renin activity and noradrenaline during beta-blocker therapy for hypertension.
    Man in't Veld AJ, Schalekamp MA.
    Postgrad Med J; 1983 May 09; 59 Suppl 3(689):140-58. PubMed ID: 6139800
    [Abstract] [Full Text] [Related]

  • 17. The influence of vasodilating beta-blockers on cardiac function and vascular resistance in essential hypertension.
    Lund-Johansen P.
    Clin Nephrol; 1992 May 09; 38 Suppl 1():S78-86. PubMed ID: 1363538
    [Abstract] [Full Text] [Related]

  • 18. The evolving role of β-adrenergic receptor blockers in managing hypertension.
    Poirier L, Lacourcière Y.
    Can J Cardiol; 2012 May 09; 28(3):334-40. PubMed ID: 22595449
    [Abstract] [Full Text] [Related]

  • 19. The role of the new beta-blockers in treating cardiovascular disease.
    Weber MA.
    Am J Hypertens; 2005 Dec 09; 18(12 Pt 2):169S-176S. PubMed ID: 16373195
    [Abstract] [Full Text] [Related]

  • 20. The development of new-onset type 2 diabetes associated with choosing a calcium channel blocker compared to a diuretic or beta-blocker.
    Kuti EL, Baker WL, White CM.
    Curr Med Res Opin; 2007 Jun 09; 23(6):1239-44. PubMed ID: 17559720
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.